All In Biotech

NDA 021171 · Hospira

Demerol

Meperidine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1942

Nov 10, 1942

Approved uses

1

Original approval plus efficacy supplements

Registered trials

105

11 Phase 3, 5 recruiting

FAERS reports

9,363

5,919 serious, 764 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DEMEROL Addiction, Abuse, and Misuse Because the use of DEMEROL Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of DEMEROL Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, ‎proper dosing and titration of DEMEROL Injection are essential [see Warnings and Precautions (5.2) ] . Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with...

What it is approved for

From the label in effect Jul 20, 2026.

DEMEROL Injection is indicated for preoperative medication, support of anesthesia, and obstetrical analgesia. DEMEROL Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DEMEROL Injection is indicated for preoperative medication, support of anesthesia, for obstetrical analgesia, and for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including DEMEROL Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Use of ‎DEMEROL Injection for an extended period of time may increase the risk of ‎toxicity (e.g., seizures) from the accumulation of the meperidine metabolite, ‎normeperidine. ( 1 , 5.1 )‎ Limitations of Use: Because of the risks of addiction, abuse, misuse , overdose, and death , which can occur at any dosage or duration and persist over the course of therapy, [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including DEMEROL Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Use of DEMEROL Injection for an extended period of time may increase the risk of toxicity (e.g., seizures) from the accumulation of the meperidine metabolite, normeperidine.

Mechanism: Meperidine hydrochloride is an opioid agonist with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 10, 1942 Original approval
4 products under this application
  • DEMEROL · MEPERIDINE HYDROCHLORIDE 75MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DEMEROL · MEPERIDINE HYDROCHLORIDE 25MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DEMEROL · MEPERIDINE HYDROCHLORIDE 100MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DEMEROL · MEPERIDINE HYDROCHLORIDE 50MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Meperidine" as an intervention, any sponsor and status, largest first.

All 105 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity3,327
  • drug ineffective1,396
  • pain1,290
  • nausea1,278
  • off label use1,014
  • hyperhidrosis987
  • drug intolerance829
  • rash813
  • overdose760
  • vomiting756
  • hypertension740
  • headache703

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004213
2005180
2006178
2007131
2008114
2009166
2010198
2011233
2012340
2013270
2014375
2015401
2016554
2017500
2018664
20191,002
2020722
2021663
2022466
2023734
2024519
2025360
2026379

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30).

  • Current · updated Nov 9, 2026

    Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30).

  • Current · updated Nov 9, 2026

    Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Demerol (Meperidine HCl/PF)

2024 spending

$33K

Beneficiaries

28

88 claims

Per beneficiary

$1,161

$7.38 per unit

View as table
YearSpending
2020$44,706
2021$44,246
2022$58,477
2023$71,081
2024$32,504

Part B: Demerol* (Meperidine HCL*) · HCPCS J2175

2024 spending

$36K

Beneficiaries

3,230

5,262 claims

Per beneficiary

$11

2024 ASP limit $6.68 per unit

View as table
YearSpending
2020$80,184
2021$70,153
2022$55,045
2023$55,224
2024$35,508

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 813 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.